HARROW, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $HROW in the last 7 days.
No SEC Form 4 filings for $HROW in the last 30 days.
See all $HROW insider activity →Harrow (HROW) completed its $30M acquisition of TYRVAYA nasal spray from Viatris, with up to $70M in milestone payments. TYRVAYA, approved for dry eye disease, complements Harrow's VEVYE product. Harrow expects $30M+ revenue from TYRVAYA in 2027, with 40 Viatris employees joining its team.
B. Riley analyst Mayank Mamtani highlighted top biotech picks ahead of 3Q26 earnings, including Axsome Therapeutics (AXSM), Cytokinetics (CYTK), Eton Pharmaceuticals (ETON), Harrow (HROW), TG Therapeutics (TGTX), and Zymeworks (ZYME). The analyst provided price targets and revenue projections for each, noting macroeconomic challenges for small and mid-cap biotech stocks.
Harrow (HROW) announced the departure of its Chief Accounting Officer, with the CFO taking over the role. The company's shares closed at $38.54, with mixed short-term momentum. Analysts suggest Harrow may be undervalued by 44%, citing strong growth potential in its ophthalmic drugs.
Recent HROW coverage spans technology, corporate actions and mergers & acquisitions.
The deal adds a FDA‑approved product and a new prescriber base, likely boosting Harrow's revenue outlook.
Revenue estimates may lift the stock.
The leadership change consolidates accounting oversight, which may raise concerns about internal controls and could affect investor sentiment.
Leadership consolidation may raise concerns about internal controls but is a routine change.
Leadership change may affect accounting oversight and investor perception.
AlphAI scores every news story that mentions HROW with an AI model for sentiment and relevance, and aggregates insider trades from HARROW, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Harrow (HROW) completed its $30M acquisition of TYRVAYA nasal spray from Viatris, with up to $70M in milestone payments. TYRVAYA, approved for dry eye disease, complements Harrow's VEVYE product. Harrow expects $30M+ revenue from TYRVAYA in 2027, with 40 Viatris employees joining its team.
2 min readB. Riley analyst Mayank Mamtani highlighted top biotech picks ahead of 3Q26 earnings, including Axsome Therapeutics (AXSM), Cytokinetics (CYTK), Eton Pharmaceuticals (ETON), Harrow (HROW), TG Therapeutics (TGTX), and Zymeworks (ZYME). The analyst provided price targets and revenue projections for each, noting macroeconomic challenges for small and mid-cap biotech stocks.
3 min readHarrow (HROW) announced the departure of its Chief Accounting Officer, with the CFO taking over the role. The company's shares closed at $38.54, with mixed short-term momentum. Analysts suggest Harrow may be undervalued by 44%, citing strong growth potential in its ophthalmic drugs.
2 min readHarrow, Inc. (HROW) announced Randall E. Pollard's departure as Chief Accounting Officer. Andrew R. Boll, the CFO, will also serve as principal accounting officer without additional compensation. No reason was given for Pollard's exit.
1 min readHARROW, INC. (HROW) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective September 4, 2026, Randall E. Pollard ceased serving as Chief Accounting Officer and principal accounting officer
1 min readHarrow (HROW) announced positive clinical study results for its IHEEZO ophthalmic gel, showing reduced patient discomfort during intravitreal injections. The study is relevant for Harrow's focus on specialty eye care and may impact its revenue mix. Investors will watch for real-world adoption in retina practices.
2 min readHarrow Inc. (NASDAQ:HROW) reported positive results from a clinical study of its ocular anesthetic IHEEZO, showing significant pain reduction compared to a control. Analysts noted the findings support long-term growth and maintained an Outperform rating. HROW shares were down 1.33% at $41.50 on Friday.
2 min readHarrow, Inc. (HROW) reported that its IHEEZO gel reduced patient discomfort by 58% compared to proparacaine in a study of 50 patients. The FDA-approved anesthetic showed statistically significant benefits at all assessment points. HROW stock closed at $41.64, up 5.36%, and was at $41.95 in pre-market trading.
1 min readHarrow (HROW) reported Q2 2026 revenue of $70.7M, up 11% YoY, with first-half revenue at $115M. Key products IHEEZO and VEVYE showed growth, with IHEEZO achieving record unit demand and VEVYE seeing a 21% sequential prescription increase. The company expects stronger revenue and profitability in the second half, driven by improved product economics, broader commercial coverage, and strategic acquisitions like TYRVAYA. Harrow reiterated its full-year guidance, anticipating sequential revenue grow
3 min readShojaei Amir (CHIEF SCIENTIFIC OFFICER) sold 11,250 shares of HARROW, INC. (HROW) at $40.00 ($0.45M total) on 2026-08-14.
1 min read
